CSF3 and myeloid sarcoma: Though concerns about potential exacerbations of MS have been raised regarding the use of granulocyte colony-stimulating factor, the overall benefits appear to outweigh the risks, as evidenced by multiple positive treatment responses in the reported cases [7,8].